Biosimilar

WASHINGTON — In this video, Micaela F. Bayard, MD, highlights a conversation on the evolution of biosimilars from ACR Convergence 2024.

The American College of Rheumatology has joined a coalition of more than 40 other organizations calling on congressional leaders to address what they see as insufficient Medicare reimbursements for biosimilars.

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.

The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.

PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.

An electronic health record tool has demonstrated the potential to automate the selection of biosimilars.

The presence of comorbidities with inflammatory rheumatic musculoskeletal diseases made little difference in biosimilar retention after a non-medical switch, according to data published in Arthritis Research & Therapy.

The FDA has approved subcutaneous and IV formulations of the Stelara biosimilar Otulfi for Crohn’s disease, ulcerative colitis and all other indications approved for the reference product, according to a press release from Fresenius Kabi.

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.